DAPT (GSI-IX): Selective γ-Secretase Inhibitor for Notch Pathway Modulation

Executive Summary: DAPT (GSI-IX) is a potent, orally bioavailable γ-secretase inhibitor (IC₅₀ = 20 nM in HEK 293 cells) that blocks amyloid precursor protein (APP) and Notch processing, reducing amyloid-β peptide production (IC₅₀ = 115 nM in cellular assays) (APExBIO). It is widely used in research on Alzheimer's disease, cancer, and immune regulation due to its robust, selective inhibition of γ-secretase. DAPT demonstrates concentration-dependent inhibition of glioma cell proliferation and suppresses tumor angiogenesis at 10 mg/kg/day in vivo. It is insoluble in water but dissolves in DMSO (≥21.62 mg/mL) and ethanol (≥16.36 mg/mL with sonication), requiring storage at -20°C. Its application in organoid and cell-fate studies underpins innovations in stem cell and translational research (Wu et al., 2019).

Biological Rationale

γ-Secretase is a multi-subunit protease complex essential for intramembrane proteolysis of key substrates, including APP and Notch receptors. Aberrant γ-secretase activity is implicated in Alzheimer's disease through excessive amyloid-β (Aβ) production and in various cancers via deregulated Notch signaling (Related Article). DAPT (GSI-IX) enables the selective blockade of γ-secretase, thus providing a precise tool for dissecting these pathways. In models of human hepatobiliary organoids derived from induced pluripotent stem cells (hiPSCs), pathway modulation by γ-secretase inhibitors like DAPT elucidates roles in cell fate, differentiation, and tissue organization (Wu et al., 2019). The ability to control these pathways is central to understanding neurodegeneration, oncogenesis, and regenerative medicine.

Mechanism of Action of DAPT (GSI-IX)

DAPT (GSI-IX) is a non-competitive, reversible inhibitor of γ-secretase. It binds to the presenilin-containing γ-secretase complex, preventing cleavage of type I transmembrane substrates, notably APP and the Notch receptor. This blockade impedes generation of neurotoxic Aβ40/Aβ42 peptides from APP and inhibits the release of the Notch intracellular domain (NICD), a key transducer of Notch signaling (APExBIO). The result is suppression of downstream gene expression involved in cell differentiation, proliferation, and apoptosis. DAPT-mediated inhibition is dose-dependent and substrate-specific, with an IC₅₀ for Notch processing and APP cleavage in the low nanomolar range. Selectivity over other protease systems is well-documented, and the compound does not require genetic manipulation for pathway modulation.

Evidence & Benchmarks

• DAPT (GSI-IX) inhibits γ-secretase with an IC₅₀ of 20 nM in HEK 293 cells (APExBIO).
• Reduces production of Aβ40 and Aβ42 peptides in cell-based models with an IC₅₀ of 115 nM (APExBIO).
• Suppresses Notch signaling in diverse cell types, modulating differentiation, autophagy, and apoptosis (Wu et al., 2019).
• Inhibits proliferation of SHG-44 human glioma cells in vitro at concentrations as low as 1.0 μM, demonstrating a concentration-dependent effect (APExBIO).
• In vivo, subcutaneous injection of 10 mg/kg/day in Balb/C mice reduces tumor angiogenesis markers, confirming anti-angiogenic activity (APExBIO).
• Applied in the generation and maturation of hiPSC-derived hepatobiliary organoids, aiding in studying liver development and disease (Wu et al., 2019).

For further context, see DAPT (GSI-IX): Transforming Translational Research, which frames DAPT's role in human iPSC-derived neuronal models. This article extends that discussion by providing direct quantitative benchmarks and storage/handling guidance.

Applications, Limits & Misconceptions

DAPT (GSI-IX) is utilized in:

• Alzheimer's disease research: Inhibits the generation of amyloid-β peptides by blocking APP cleavage (Related Article). This article expands by detailing storage and solubility parameters essential for reproducibility.
• Cancer research: Modulates Notch signaling to study tumorigenesis, cell proliferation, and angiogenesis.
• Autoimmune disorder research: Dissects Notch-dependent immune regulation and differentiation.
• Organoid and cell fate engineering: Enables precise modulation of differentiation pathways in hiPSC-derived systems (Wu et al., 2019).

Common Pitfalls or Misconceptions

• DAPT is not water-soluble; attempting to dissolve in aqueous buffers leads to precipitation and loss of activity (APExBIO).
• Prolonged storage of working solutions above -20°C reduces potency; always store stock solutions at or below -20°C.
• Notch-independent phenotypes may not be responsive to DAPT; pathway specificity must be experimentally validated.
• DAPT does not substitute for genetic knockout of γ-secretase components in all contexts.
• Off-target effects at high concentrations (>10 μM) may confound interpretation in non-target tissues.

Workflow Integration & Parameters

DAPT (GSI-IX) is supplied by APExBIO as a lyophilized solid (MW: 432.46). For in vitro use, dissolve at ≥21.62 mg/mL in DMSO or ≥16.36 mg/mL in ethanol (sonication recommended). Working concentrations typically range from 0.1–10 μM, depending on cell type and endpoint. For in vivo studies, subcutaneous administration at 10 mg/kg/day has demonstrated efficacy in tumor models. Store powders at -20°C and avoid repeated freeze-thaw cycles for solutions. For experimental models such as hiPSC-derived organoids, DAPT is added during defined differentiation windows to modulate Notch-dependent lineage specification (Wu et al., 2019).

For advanced troubleshooting and translational applications, see DAPT (GSI-IX): Selective γ-Secretase Inhibitor for Precise Disease Modeling, which focuses on workflow mastery. The present article clarifies storage, solubility, and concentration-dependent effects in detail.

Conclusion & Outlook

DAPT (GSI-IX) remains a gold-standard, selective γ-secretase inhibitor, empowering researchers to interrogate Notch and amyloidogenic pathways with precision. Its robust performance in both cell-based and in vivo systems, coupled with detailed handling guidance, underpins its widespread adoption in neurodegeneration, oncology, and stem cell biology. As organoid and regenerative medicine models advance, DAPT's role in pathway modulation is poised to expand further, driving discovery in disease modeling and therapeutic innovation (Wu et al., 2019). For comprehensive technical data and ordering, see the DAPT (GSI-IX) A8200 product page from APExBIO.